Acino Publishes Second Annual Sustainability Report
Report underscores Acino’s continued commitment to Environmental, Social, and Governance goals, including a firm commitment to reaching full carbon neutrality by 2050.
Zurich, Switzerland – 1 October 2024: Acino, a Swiss pharmaceutical company headquartered in Zurich, today announced the launch of its second annual Sustainability Report, highlighting the Company’s current Environmental, Social, and Governance (ESG) initiatives and goals for the future.
The 2023 Sustainability Report reaffirms Acino’s commitment to its ESG strategy, which is built around three pillars:
- Global Health Leadership: A clear commitment to deliver and contribute as an actor in the global health agenda, provide high-quality medicines in emerging markets, and support the WHO’s Universal Health Coverage (UHC) ambitions, while operating sustainably.
- Move to Net Zero: Multi-faceted initiatives to reduce waste, recycle resources, increase energy efficiency, and decarbonize our value chain while embedding sustainable business practices in the way Acino operates.
- Care for All: A promise to create lasting, positive outcomes for all stakeholders, including patients, healthcare professionals, employees, and the communities where Acino operates, through educational support, diversity and inclusion and sustainable business practices.
Andrew Bird, CEO (ai) of Acino, commented: “Responsible operations are integral to Acino’s purpose of delivering proven and innovative medicines to emerging markets. It is also essential to our reputation as a trusted partner of choice for pharmaceutical companies, healthcare providers and patients alike. This year’s Sustainability Report delivers a comprehensive view of the impressive global efforts taken towards realising our long-term social and environmental goals. Our collective actions, both at a corporate and regional level, are essential to creating sustainable value for all.”
Key highlights of the 2023 Sustainability Report include:
- Elevating Sustainability Governance, with the head of the function joining Acino’s Global Leadership Team and reporting into the CEO.
- Increasing Acino’s rating by EcoVadis, an industry leading sustainability platform. .
- Achieving 100% renewable energy sourcing at our Swiss manufacturing and packaging sites, and implementing significant energy saving measures at our Ukrainian manufacturing site, thereby reducing our overall Scope 1 and 2 emissions.
- Launching a new Supplier Code of Conduct and evaluating 100% of our new high-risk suppliers according to the standards of the Pharmaceutical Supply Chain Initiative.
The full Sustainability Report can be read here.
-ENDS-
About Acino
Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Ukraine, the CIS Region, and Latin America. We deliver quality pharmaceuticals to promote affordable healthcare in these markets. We leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing. For more information, please visit www.acino.swiss.
Acino is part of Arcera, a global company in the life sciences sector headquartered in Abu Dhabi, United Arab Emirates. Arcera was established by ADQ, an Abu Dhabi-based investment and holding company, to build a global life sciences powerhouse poised to make significant contributions to realising the UAE’s aspiration to emerge as a frontrunner in science and technology. To learn more about Arcera, please visit www.arceralifesciences.com.
For more information, please contact:
Larisa Bernstein, Global Head of Communications, Acino
communications@acino.swiss